Marijuana Co of America Stock (OTC: MCOA)

Marijuana Co of America Stock (OTC:MCOA), Trade Ideas

Marijuana Company of America Inc is a marijuana marketing and distribution company. Through its subsidiary, the company delivers all the benefits of industrial hemp-derived cannabinoid products to the world through its unique marketing and distribution platform through cDistro. It also provides turn-key services to the legal cannabis and hemp industry, as well as, strategically investing in synergistic companies to develop a diverse portfolio of subsidiaries and joint ventures that create value for our shareholders.

Cannabis

Earnings

News

Penny Stocks

Markets

MCOA

Marijuana Company of America Inc. (OTC PINK: MCOA) announced on Tuesday its financial results and other financial highlights for the third quarter and nine months ending September 30, 2022.

Marijuana Company Of America Reports Q3 Earnings, CEO Says &#39;Shareholders Should Be Happy&#39;

Small Cap

Exclusives

General

ACRHF

AKAN

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

CNBS

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

FFNTF

FLGC

GNLN

GTBIF

JUSHI HLDGS INC CL B by Jushi Holdings Inc.

JUSHF

KHIRON LIFE SCIENCES CORP by Khiron Life Sciences Corp.

KHRNF

MAPS

MRMD

NDVAF

PSDN

TCNNF

TLLTF

UGRO

“We’ve run our numbers and estimate that roughly $1 billion in deals will be closed on September 13 and 14 in Chicago.

Benzinga CEO Predicts $1B In Cannabis Deals Closing In Just 2 Days In September: Find Out Where And How!

Entrepreneurship

Events

TSXV:KHRN

After a prosperous event in Miami this past April, the Benzinga Cannabis Capital Conference is ready to do it again in Chicago on September 13-14.

Five Latinxs To Watch In The Cannabis Space: Meet The Who&#39;s Who At Benzinga&#39;s Cannabis Capital Conference In Chicago

MARIJUANA CO OF AMER INC by Marijuana Company of America, Inc.

Marijuana Company of America Inc

<h1 class="wp-block-heading">Top Stories for April 24, 2024:</h1>
<ol>
<li>American Battery Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABAT#NASDAQ">ABAT</a>) updated <a href="https://www.benzinga.com/news/24/04/38404516/american-battery-technology-company-publishes-updated-initial-assessment-and-economic-analysis-for-t">its initial assessment</a> for the Tonopah Flats Lithium Project (TFLP).</li>
</ol>
It refined the project&#8217;s scope to use only measured and indicated mineral resources, excluding the more speculative inferred resources.&nbsp;
This strategy improves the project's economics by enhancing access to higher-quality resources and optimizing processing at its newly built demonstration facility. 
Key updates include a 7% reduction in total processed claystone, an 8% increase in lithium grade, a 7% decrease in production costs and a 6% rise in the project&#8217;s net present value to $4.67 billion.
<ol start="2">
<li>Steel Dynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) reported first-quarter results, with net sales of $4.7 billion and net income of $584 million. </li>
</ol>
Highlights include 3.3 million tons of steel shipments, operating income of $751 million and adjusted EBITDA of $879 million.&nbsp;
The company&#8217;s financial health was further supported by liquidity of $3.1 billion and shareholder returns through $298 million in stock repurchases and an 8% dividend increase.&nbsp;
Demand was solid across sectors, particularly automotive and construction, driving sequential improvements in earnings and operational performance.
Also Read:<a href="https://www.benzinga.com/topic/mining"> </a><a href="https://www.benzinga.com/news/24/04/38390383/copper-prices-approach-2-year-highs-whats-behind-analysts-12-000-price-prediction-for-2026">Copper Prices Approach 2-Year Highs: What&#8217;s Behind Analyst&#8217;s $12,000 Price Prediction For 2026?</a>
<ol start="3">
<li>Gold Royalty Corp (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GROY#AMEX">GROY</a>) entered into a three-year mutual cooperation agreement with Taurus Mining Royalty Fund that allows both parties to co-invest in precious metals royalties and streams. </li>
</ol>
The agreement focuses on assets valued at $30 million or more and provides a framework for identifying and evaluating co-investment opportunities, with the option for each party to invest 25% to 50% in selected transactions.&nbsp;
Additionally, any future sales of interests acquired through this partnership will offer first rights to the other partner.
<ol start="4">
<li>Coeur Mining Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDE#NYSE">CDE</a>) released its 2023 ESG Report, emphasizing its progress in environmental, social and governance efforts aligned with shareholder value. </li>
</ol>
The report highlights Coeur&#8217;s achievement of the lowest injury rate among peers at 0.46 and its adoption of the Global Industry Standard on Tailings Management (placing it among the top 17% of non-International Council on Mining and Metals companies).
The company also shared its commitment to biodiversity through the Biodiversity Management Standard and advancements in climate resilience, aiming for a 35% reduction in GHG emissions by the end of 2024.
Now Read:<a href="https://www.benzinga.com/"> </a><a href="https://www.benzinga.com/m-a/24/04/38405991/equinox-gold-snaps-up-greenstone-gold-mines-for-995m-in-incredibly-rare-deal">Equinox Gold Snaps Up Greenstone Gold Mines For $995 Million In &#8216;Incredibly Rare&#8217; Deal</a>
Benzinga Mining is the bridge between mining companies and retail investors. Reach out to <a href="mailto:licensing@benzinga.com">licensing@benzinga.com</a> to get connected with the Benzinga community!
Photo: Jose Luis Stephens via Shutterstock.

Commodities

ABAT

GROY

STLD

American Battery Optimizes Lithium Project; Steel Dynamics Reports Q1 Results; Gold Royalty Teams Up With Taurus Mining And More: Wednesday's Top Mining Stories

Helix Energy Solns Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLX#NYSE">HLX</a>) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $0.02 by 250 percent. The company reported quarterly sales of $296.211 million which missed the analyst consensus estimate of $296.725 million by 0.17 percent. This is a 18.44 percent increase over sales of $250.084 million the same period last year.

Earnings Misses

Helix Energy Solns Gr Q1 2024 Adj EPS $(0.03) Misses $0.02 Estimate, Sales $296.211M Miss $296.725M Estimate

National Bank Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBHC#NYSE">NBHC</a>) reported quarterly earnings of $0.82 per share which beat the analyst consensus estimate of $0.76 by 7.89 percent. This is a 22.64 percent decrease over earnings of $1.06 per share from the same period last year. The company reported quarterly sales of $101.724 million which missed the analyst consensus estimate of $103.683 million by 1.89 percent. This is a 7.15 percent decrease over sales of $109.554 million the same period last year.

Earnings Beats

NBHC

National Bank Holdings Q1 2024 GAAP EPS $0.82 Beats $0.76 Estimate, Sales $101.724M Miss $103.683M Estimate

In June 2022, New York Gov. Kathy Hochul announced a deal had finally been reached to <a href="https://www.benzinga.com/markets/cannabis/22/01/24932856/new-york-gov-kathy-hochul-pledges-200m-to-boost-social-equity-efforts-as-part-of-cannabis-legali">fund a $200 million public-private effort</a>, which would finance cannabis dispensaries run by the people who have been the most impacted by the war on drugs.
The much-anticipated public-private fund is now coming under scrutiny following an <a href="https://www.thecity.nyc/2024/04/24/cannabis-fund-social-equity-dispensary/">investigation</a> by THE CITY&#8217;s Rosalind Adams, which uncovered a "lopsided deal" favoring the private equity firm Chicago Atlantic Group and raising concerns about the state's social equity goals. 
The agreement heavily favors Chicago Atlantic, leaving the state exposed to significant risks, noted the outlet.
Even the New York Office of Cannabis Management (OCM) cast doubts on the fund&#8217;s viability according to internal OCM documents that questioned whether the deal had overstated the potential revenue and profit potential.
<h1 class="wp-block-heading">What Happened</h1>
New York state, unable to secure a private equity partner, agreed to a $50 million loan from Chicago Atlantic at a 15% interest rate, with all risk borne by the state.
Critics, including Reinvent Albany, an organization that advocates for government transparency and accountability, deemed the deal to have been detrimental to the state and prospective dispensary owners. Legal experts and consultants likened it to distressed debt lending.
Despite the skepticism and advice against the arrangement, negotiations ultimately led to a secret agreement benefiting Chicago Atlantic.
Previously, THE CITY revealed how cannabis licensees who accept loans from the social equity fund are burdened with high construction costs that they don't control and with interest rates that exceed the state's initial estimates.
"Everyone is worried about defaulting because of the rules and regulations of this loan," said Roland Conner, who runs <a href="https://www.benzinga.com/markets/cannabis/23/01/30496199/ny-gov-hochul-announces-opening-of-first-cannabis-shop-owned-by-person-impacted-by-war-on-drugs">Smacked on Bleecker Street</a> in Greenwich Village, the first legal dispensary owned by a person affected by the drug war.
<h1 class="wp-block-heading">Who's Responsible?</h1>
Details of the deal are still secret, with New York state authorities denying Freedom of Information Law requests. The state comptroller&#8217;s office and key lawmakers say they were not informed or involved in the making of the deal, exposing a shocking lack of oversight.
Meanwhile, Chicago Atlantic secured favorable terms, including leasing rights and a $100 million commitment for property development, raising yet more concerns about profiteering at the expense of marginalized communities.
<h1 class="wp-block-heading">Corruption Or Ineptitude?</h1>
The handling of New York&#8217;s cannabis program seems to reflect a corrosive mix of both ineptitude and potential corruption. While officials may have sought to support marginalized groups, their actions suggest a lack of due diligence and transparency.
One element of the story, which you can read in full <a href="https://www.thecity.nyc/2024/04/24/cannabis-fund-social-equity-dispensary/">here</a>, is that social equity applicants are furious.
A Queens shop owner, Dalessio, who was awarded a retail license designated for people impacted by past drug convictions told THE CITY that after a year of back and forth with the fund, he walked away from the deal.
"It just left such a bad taste in my mouth. I warned everyone I could to stay away from this deal," he said.
Photo: Courtesy of Branding Pot via Shutterstock

Government

Politics

Legal

Cannabis Saga In The Empire State: Corruption Or Ineptitude? Private Equity Tramples Social Equity, Report Reveals

Alamos Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGI#NYSE">AGI</a>) reported quarterly Adj earnings of $0.13 per share which met the analyst consensus estimate. The company reported quarterly sales of $277.600 million which beat the analyst consensus estimate of $272.000 million by 2.06 percent. This is a 10.38 percent increase over sales of $251.500 million the same period last year.

Alamos Gold Q1 Adj EPS $0.13, Inline, Sales $277.600M Beat $272.000M Estimate

Piper Sandler analyst Clarke Jeffries maintains Tyler Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) with a Overweight and maintains $520 price target.

Price Target

Analyst Ratings

Piper Sandler Maintains Overweight on Tyler Technologies, Maintains $520 Price Target

Rogers, who will continue to serve as a director of Mativ and will assume the role of Audit Committee Chair.

Management

MATV

Mativ Holdings Appoints Kimberly Ritrievi As Chair Of Board, Succeeding John Rogers

First Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBMS#NASDAQ">FBMS</a>) reported quarterly earnings of $0.65 per share which beat the analyst consensus estimate of $0.59 by 10.17 percent. This is a 24.42 percent decrease over earnings of $0.86 per share from the same period last year. The company reported quarterly sales of $57.341 million which missed the analyst consensus estimate of $59.927 million by 4.32 percent. This is a 11.68 percent decrease over sales of $64.926 million the same period last year.

FBMS

First Bancshares Q1 2024 Adj EPS $0.65 Beats $0.59 Estimate, Sales $57.341M Miss $59.927M Estimate

Guidance

Veris Residential Raises FY24 Core FFO Per Share Outlook From $0.48-$0.53 To $0.50-$0.54, Est $0.53

Colony Bankcorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBAN#NASDAQ">CBAN</a>) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.31 by 6.45 percent. This is a 6.45 percent increase over earnings of $0.31 per share from the same period last year. The company reported quarterly sales of $28.141 million which beat the analyst consensus estimate of $27.600 million by 1.96 percent. This is a 0.30 percent decrease over sales of $28.227 million the same period last year.

CBAN

Colony Bankcorp Q1 2024 Adj EPS $0.33 Beats $0.31 Estimate, Sales $28.141M Beat $27.600M Estimate

Needham analyst Mike Matson maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and raises the price target from $71 to $82.

Needham Maintains Buy on Boston Scientific, Raises Price Target to $82

CVB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVBF#NASDAQ">CVBF</a>) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.34 by 2.94 percent. This is a 16.67 percent decrease over earnings of $0.42 per share from the same period last year. The company reported quarterly sales of $126.574 million which beat the analyst consensus estimate of $116.576 million by 8.58 percent. This is a 8.89 percent decrease over sales of $138.930 million the same period last year.

CVBF

CVB Financial Q1 2024 GAAP EPS $0.35 Beats $0.34 Estimate, Sales $126.574M Beat $116.576M Estimate

Bridgewater Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWB#NASDAQ">BWB</a>) reported quarterly earnings of $0.24 per share which missed the analyst consensus estimate of $0.25 by 4 percent. This is a 35.14 percent decrease over earnings of $0.37 per share from the same period last year. The company reported quarterly sales of $26.181 million which missed the analyst consensus estimate of $27.033 million by 3.15 percent. This is a 13.50 percent decrease over sales of $30.267 million the same period last year.

Bridgewater Bancshares Q1 2024 GAAP EPS $0.24 Misses $0.25 Estimate, Sales $26.181M Miss $27.033M Estimate

U.S. President Joe Biden&#8216;s recent signing of legislation has thrown ByteDance&#8217;s TikTok into the spotlight, with CEO Shou Zi Chew saying <a href="https://www.benzinga.com/news/24/03/38001945/amid-us-china-tussle-tiktok-content-creators-worry-about-bread-and-butter-if-app-ban-succeeds">the platform will fight back.</a>
&#8220;Make no mistake, this is a ban, a ban on TikTok and a ban on you and your voice,&#8221; the CEO said in a two-minute&nbsp;<a href="https://www.tiktok.com/@tiktok/video/7361448925972155679" target="_blank" rel="noreferrer noopener">video</a>&nbsp;posted to TikTok&#8217;s main corporate account.
See Also: <a href="https://www.benzinga.com/news/24/04/38372058/analyst-predicts-tiktok-shutdown-in-us-by-next-year-ahead-of-senate-vote-will-not-operate-here">Analyst Predicts TikTok Shutdown In US By Next Year Ahead Of Senate Vote: &#8216;Will Not Operate Here&#8230;&#8217;</a>
Chew&#8217;s statement, delivered Wednesday, April 24, continued: &#8220;Politicians may say otherwise. But don't get confused. Many who sponsored the bill admit a TikTok ban is their ultimate goal.&#8221;
The legislation, part of a $95 million foreign aid package supporting Israel and Ukraine, was widely supported by the U.S. Senate and the House of Representatives.
It gives ByteDance, TikTok&#8217;s parent company, 270 days to find new owners. If ByteDance fails to comply, TikTok faces removal from Apple Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Alphabet Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google app stores in the U.S., People magazine <a href="https://people.com/tiktok-ceo-says-we-arent-going-anywhere-biden-signs-potential-ban-into-law-8638226">reported. </a>
Additionally, there&#8217;s a provision for a three-month extension if a sale is in progress by the initial deadline.
<h1 class="wp-block-heading">ByteDance&#8217;s TikTok Fights Back Against Ban</h1>
TikTok&#8217;s uncertain future stems from discussions that began during the COVID-19 pandemic. Former President Donald Trump initially proposed banning the app in April 2020, a move later paused by the Biden administration in February 2021. Currently, TikTok boasts 170 million American users.
The legislation presents concerns about security, with fears that TikTok could be used for Chinese surveillance or data access. TikTok denies these allegations, and the Chinese government asserts there&#8217;s no evidence supporting claims of national security threats. 
TikTok plans to challenge the legislation, citing freedom of speech. In his video, Chew expressed confidence in their legal fight: &#8220;Rest assured, we aren&#8217;t going anywhere.&#8221; 
&#8220;We are confident and we will keep fighting for your rights in the courts&#8230; The facts and the U.S. Constitution are on our side, and we expect to prevail again,&#8221; he added. 
<h1 class="wp-block-heading">Can I Keep Using TikTok? Exploring The Ban&#8217;s Impact</h1>
Don&#8217;t worry, TikTok won&#8217;t just vanish from your phone overnight.
It&#8217;s likely to be at least a year before any ban takes effect, with potential legal challenges possibly extending the timeline further. While TikTok has succeeded in court before, this marks a new challenge against federal legislation.
Concerning your TikTok app, it&#8217;s unlikely to disappear from your phone immediately. However, if the ban goes into effect it may vanish from Apple and Google&#8217;s app stores, meaning no new downloads, updates, or fixes, as <a href="https://www.nbcnewyork.com/news/national-international/tiktok-ban-us-what-to-know/5350848/#:~:text=No%2C%20TikTok%20will%20not%20suddenly%20disappear%20from%20your%20phone.">per</a> NBC New York. 
Over time, this could pose security risks and usability challenges.
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38358239/microsoft-and-oracle-could-be-tiktoks-likely-buyers-but-real-winners-would-be-mark-">Microsoft And Oracle Could Be TikTok&#8217;s &#8216;Likely Buyers,&#8217; But Real Winners Would Be Mark Zuckerberg And Sundar Pichai</a>
Photo: <a href="https://www.shutterstock.com/es/g/salarko">salarko</a> on Shutterstock.

Asia

Regulations

Social Media

AAPL

GOOGL

TikTok Fights Back, 'We Aren't Going Anywhere': What's Next For Users?

Barrington Research analyst James Goss maintains Travelzoo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZOO#NASDAQ">TZOO</a>) with a Outperform and lowers the price target from $14 to $12.

TZOO

Barrington Research Maintains Outperform on Travelzoo, Lowers Price Target to $12

Nanobiotix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTX#NASDAQ">NBTX</a>) reported quarterly losses of $(1.17) per share which beat the analyst consensus estimate of $(1.66) by 29.52 percent. This is a 32.37 percent increase over losses of $(1.73) per share from the same period last year. The company reported quarterly sales of $39.323 million which beat the analyst consensus estimate of $13.680 million by 187.45 percent. This is a 681.30 percent increase over sales of $5.033 million the same period last year.

NBTX

Nanobiotix FY 2023 GAAP EPS $(1.17) Beats $(1.66) Estimate, Sales $39.323M Beat $13.680M Estimate

PennyMac Mortgage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PMT#NYSE">PMT</a>) reported quarterly earnings of $0.39 per share which beat the analyst consensus estimate of $0.32 by 21.88 percent. This is a 22 percent decrease over earnings of $0.50 per share from the same period last year. The company reported quarterly sales of $74.205 million which missed the analyst consensus estimate of $85.366 million by 13.07 percent. This is a 17.88 percent decrease over sales of $90.366 million the same period last year.

PennyMac Mortgage Q1 2024 GAAP EPS $0.39 Beats $0.32 Estimate, Sales $74.205M Miss $85.366M Estimate

CDMO

Avid Bioservices Maintains FY24 Revenue Guidance Of $137M-$147M, Est $138.656M

Pathward Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASH#NASDAQ">CASH</a>) reported quarterly earnings of $2.56 per share which beat the analyst consensus estimate of $2.30 by 11.3 percent. This is a 28.64 percent increase over earnings of $1.99 per share from the same period last year. The company reported quarterly sales of $247.246 million which beat the analyst consensus estimate of $240.460 million by 2.82 percent. This is a 8.23 percent increase over sales of $228.443 million the same period last year.

CASH

Pathward Financial Q2 2024 GAAP EPS $2.56 Beats $2.30 Estimate, Sales $247.246M Beat $240.460M Estimate

Avid Bioservices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDMO#NASDAQ">CDMO</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.05) by 80 percent. The company reported quarterly sales of $33.800 million which beat the analyst consensus estimate of $33.452 million by 1.04 percent. This is a 11.09 percent decrease over sales of $38.018 million the same period last year.

Avid Bioservices Q3 2024 GAAP EPS $(0.09) Misses $(0.05) Estimate, Sales $33.800M Beat $33.452M Estimate

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Unless you regularly invest in or research&nbsp;<a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> it&rsquo;s likely you aren&rsquo;t familiar with most companies in the space. These penny stock picks aren&rsquo;t household names because by and large they aren&rsquo;t big companies and their products and services are largely foreign to consumers. That said, these stocks remain interesting, partly because they&rsquo;re so cheap. Any stock trading at a fraction of a penny, or in the low-single-digit realm can appreciate rapidly and provide big upside in short amounts of time.
Risky? Sure. But more than that, these penny stock picks provide intrigue and excitement for investors willing to accept the risk.
I&rsquo;m generally not much into gambling, and these stocks certainly represent gambles more so than investments. However, for those willing to accept the astronomical risk with these stocks, there might be something to consider.
Let&rsquo;s dive in.
<a href="https://investorplace.com/stock-quotes/mcoa-stock-quote/">MCOA</a>
Marijuana Company of America
$0.0002
<a href="https://investorplace.com/stock-quotes/mlfb-stock-quote/">MLFB</a>
Major League Football
$0.0007
<a href="https://investorplace.com/stock-quotes/autl-stock-quote/">AUTL</a>
Autolus Therapeutics
$2.87

<h2>Marijuana Company of America (MCOA)</h2>
<div><img src="https://investorplace.com/wp-content/uploads/2021/02/marijuana-cannabis-stocks-1600-300x169.png" alt="marijuana stocks Hand gently holding rich soil for his marijuana plants" width="300" height="169"><div>Source: Jetacom Autofocus / Shutterstock.com</div></div>
<a href="https://investorplace.com/industries/healthcare/cannabis/">Cannabis stocks</a>&nbsp;including&nbsp;Marijuana Company of America&nbsp;(OTCMKTS:<a href="https://investorplace.com/stock-quotes/mcoa-stock-quote/">MCOA</a>) have been a source of investor intrigue for several years following legalization across many jurisdictions.
I&rsquo;d venture to guess that Marijuana Company of America isn&rsquo;t one of the <a href="https://investorplace.com/industries/healthcare/cannabis/">cannabis stocks</a> that you&rsquo;ve heard of. It&rsquo;s a cultivation, processing, and dispensary firm with just a few employees. Furher, it has a very small $1.98 million market capitalization, meaning there&rsquo;s simply very little money invested in the company right now.
That isn&rsquo;t necessarily a problem. However, the risks seem quite evident for this company, given how difficult it is to find information on the company. The most recent information I could find is from <a href="https://www.investorbrandnetwork.com/clients/marijuana-company-of-america-inc/">2022</a>&nbsp;and wasn&rsquo;t issued by the company itself.
Anyway, what is interesting about MCOA shares is that they trade for a fraction of a penny, currently $0.0002. Over the past month, there have been multiple instances where prices have doubled in a very short time span. While that&rsquo;s probably due to liquidity and other factors, this is a highly-speculative stock that&rsquo;s provided proven double-up potential for speculators in recent weeks.

<h2>Major League Football (MLFB)</h2>
<div><img src="https://investorplace.com/wp-content/uploads/2023/02/football-super-bowl-stadium-1600-300x169.jpg" alt="Football player holding football in dark stadium with stark lighting" width="300" height="169"><div>Source: shutterstock.com/Sergey Nivens</div></div>
I&rsquo;m also going to guess that readers have never heard of Major League Football&nbsp;(OTCMKTS:<a href="https://investorplace.com/stock-quotes/mlfb-stock-quote/">MLFB</a>) or its stock either. That&rsquo;s because information regarding the business and the stock are very difficult to locate. That&rsquo;s about as clear an indication of risk as there is. Caveat emptor applies here.
That said, MLFB stock continues to trade at a fraction of a penny. Like the aforementioned cannabis stock, shares of MLFB stock trade at an extremely inexpensive level, around $0.0007 per share. This stock has bounced around between the $0.0006 and $0.0009 levels in recent days, indicating the kind of return potential this high-risk stock provides.
Zooming out, this company&rsquo;s stock price has been even more volatile in recent months. Shares of MLFB stock tripled within a three week span in March and April. Then they declined by two-thirds in the following weeks. Again, I can&rsquo;t find much information on this company at all, suggesting this is a stock that is best-suited for true risk takers.
For those interested, I found this&nbsp;<a href="https://www.secform4.com/penny-stock-screener">list</a>&nbsp;of similarly low-priced stocks that provide potentially massive one day gains.

<h2>Autolus Therapeutics (AUTL)</h2>
<div><img src="https://investorplace.com/wp-content/uploads/2021/11/shutterstock_1667119063-300x169.png" alt="Pipette adding fluid to one of several test tubes; biotech NVTA Stock" width="300" height="169"><div>Source: motorolka / Shutterstock.com</div></div>
Autolus Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/autl-stock-quote/">AUTL</a>) stock looks like an impeccably-run firm in comparison to the two firms above. Information is easy to source, and although this company certainly appears to be ultra-risky, it is relatively less so.
Autolus Therapeutics is a biotech firm developing therapeutics that program T cells within patients to kill cancer cells. It trades for $2.87 per share, but might be worth as much as <a href="https://www.wsj.com/market-data/quotes/AUTL/research-ratings">$12</a>.
Fundamentally, Autolus Therapeutics is what many investors might expect from a young biotech company. The stock provides plenty of promise, but that promise comes alongside a lack of results. It receives minimal grant and licensing income while racking up tens of millions of dollars in quarterly <a href="https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-reports-first-quarter-2023-financial">losses</a>.
<a href="https://investorplace.com/industries/healthcare/biotech/">Biotech stocks</a> are notoriously difficult to predict. Investors should logically believe that positive news suggesting continued progress toward commercialization will increase share prices. That isn&rsquo;t necessarily the case with this company, as positive June 2 <a href="https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-presents-positive-results-pivotal-phase-2">news</a> regarding a pivotal study didn&rsquo;t budge share prices. Nevertheless, AUTL stock is worth a speculative bet, due to its raw upside potential. It&rsquo;s a gamble, but far less of a gamble than the other companies on this list.
<a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a>
On Penny Stocks and Low-Volume Stocks:&nbsp;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&nbsp;<a href="http://investorplace.com/">InvestorPlace.com</a>&rsquo;s writers disclose this fact and warn readers of the risks.
Read More:&nbsp;Penny Stocks &mdash; <a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">How to Profit Without Getting Scammed</a>
On the date of publication, Alex Sirois did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"> Publishing Guidelines</a>.
<div>
Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.
</div>
<h3>More From InvestorPlace</h3>
<ul><li>
						<a href="https://investorplace.com/2022/07/little-known-apple-project/?cid=MKT639809&amp;eid=MKT739310">Buy This $5 Stock BEFORE This Apple Project Goes Live</a>
					</li>
<li>
						<a href="https://investorplace.com/2023/04/one-of-the-worlds-biggest-tech-breakthroughs-could-be-happening-in-americas-heartland/?cid=MKT714907&amp;eid=MKT739331">Wall Street Titan: Here&rsquo;s My #1 Stock for 2023</a>
					</li>
<li>
						<a href="https://investorplace.com/2022/06/this-could-be-the-best-deal-in-the-history-of-independent-investing-research/?cid=MKT638063&amp;eid=MKT739342">The $1 Investment You MUST Take Advantage of Right Now</a>
					</li>
<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT739347">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
</ul><div>
<div>
<div></div>
<div></div>
</div>
</div>

The post <a href="https://investorplace.com/2023/06/3-top-penny-stock-picks-you-havent-heard-of/">3 Top Penny Stock Picks You Haven&#8217;t Heard Of</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.